{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:31:19Z","timestamp":1794918679945,"version":"4.9.1"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0065157","type":"journal-article","created":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T04:23:45Z","timestamp":1370060625000},"page":"e65157","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":63,"title":["Improved Production Process for Native Outer Membrane Vesicle Vaccine against Neisseria meningitidis"],"prefix":"10.1371","volume":"8","author":[{"given":"Bas","family":"van de Waterbeemd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijsbert","family":"Zomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kaaijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ruiterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 H.","family":"Wijffels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germie P. J. M.","family":"van den Dobbelsteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"MP Girard","year":"2006","journal-title":"Vaccine"},{"key":"ref2","first-page":"195","article-title":"Vaccine against group B <italic>Neisseria meningitidis<\/italic>: protection trial and mass vaccination results in Cuba","volume":"14","author":"GV Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"G Bjune","year":"1991","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"V Thornton","year":"2006","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from <italic>Neisseria meningitidis<\/italic>","volume":"27","author":"J Holst","year":"2009","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0264-410X(89)90194-1","article-title":"Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay","volume":"7","author":"K Saukkonen","year":"1989","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7\u20132,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"DR Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","article-title":"Construction of <italic>Neisseria meningitidis<\/italic> strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine","volume":"13","author":"P van der Ley","year":"1995","journal-title":"Vaccine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"K Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","article-title":"Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs","volume":"25","author":"GP van den Dobbelsteen","year":"2007","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"CL Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie J, <etal>et al<\/etal>.. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine.","DOI":"10.1016\/j.vaccine.2010.05.006"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1128\/IAI.72.10.5955-5962.2004","article-title":"Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design","volume":"72","author":"R Urwin","year":"2004","journal-title":"Infect Immun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/432102","article-title":"Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870","volume":"192","author":"VC Hou","year":"2005","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"J Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Snape MD, Dawson T, Oster P, Evans A, John TM, <etal>et al<\/etal>.. (2010) Immunogenicity of 2 Investigational Serogroup B Meningococcal Vaccines in the First Year of Life: A Randomized Comparative Trial. Pediatr Infect Dis J.","DOI":"10.1097\/INF.0b013e3181f59f6d"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"X Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/erv.11.41","article-title":"Meningococcal serogroup B vaccines: will they live up to expectations?","volume":"10","author":"WD Zollinger","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Frasch CE, Van Alphen L, Holst J, Poolman J, Rosenqvist E (2001) Meningococcal Vaccines, Methods and Protocols. Totowa, NJ:Humana Press Inc: 81\u2013107.","DOI":"10.1385\/1-59259-148-5:81"},{"key":"ref20","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine &quot;Folkehelsa&quot;: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"JH Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a <italic>Neisseria meningitidis<\/italic> hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"I Claassen","year":"1996","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1016\/j.vaccine.2010.04.082","article-title":"Improved OMV vaccine against <italic>Neisseria meningitidis<\/italic> using genetically engineered strains and a detergent-free purification process","volume":"28","author":"B van de Waterbeemd","year":"2010","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1128\/IAI.69.10.5981-5990.2001","article-title":"Modification of lipid A biosynthesis in <italic>Neisseria meningitidis<\/italic> lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity","volume":"69","author":"P van der Ley","year":"2001","journal-title":"Infect Immun"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4161\/hv.7.8.16086","article-title":"Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants","volume":"7","author":"P van der Ley","year":"2011","journal-title":"Hum Vaccin"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.micro.091208.073413","article-title":"Biological functions and biogenesis of secreted bacterial Outer Membrane Vesicles","volume":"64","author":"A Kulp","year":"2010","journal-title":"Annual Review of Microbiology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/IAI.73.7.4070-4080.2005","article-title":"Characterization of native outer membrane vesicles from lpxL mutant strains of <italic>Neisseria meningitidis<\/italic> for use in parenteral vaccination","volume":"73","author":"M Fisseha","year":"2005","journal-title":"Infect Immun"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Koeberling O, Giuntini S, Seubert A, Granoff DM (2008) Meningococcal OMV Vaccines from Mutant Strains Engineered to Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2. Clin Vaccine Immunol.","DOI":"10.1128\/CVI.00403-08"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/IAI.00682-10","article-title":"Lipoproteins of bacterial pathogens","volume":"79","author":"A Kovacs-Simon","year":"2010","journal-title":"Infect Immun"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, <etal>et al<\/etal>.. (2010) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine.","DOI":"10.1016\/j.vaccine.2010.12.039"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pinto VB, Moran EE, Cruz F, Wang XM, Fridman A, <etal>et al<\/etal>.. (2011) An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine.","DOI":"10.1016\/j.vaccine.2011.07.124"},{"key":"ref31","unstructured":"Zollinger WD (2003) Vaccine against gram negative bacteria - US patent: US6,558,677 B2."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"R Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/j.vaccine.2011.04.095","article-title":"Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys","volume":"29","author":"O Koeberling","year":"2011","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1016\/j.vaccine.2007.06.008","article-title":"Scale-up for bulk production of vaccine against meningococcal disease","volume":"25","author":"GJ Baart","year":"2007","journal-title":"Vaccine"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1016\/j.vaccine.2012.03.028","article-title":"Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis","volume":"30","author":"B van de Waterbeemd","year":"2012","journal-title":"Vaccine"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.vaccine.2012.12.031","article-title":"Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"31","author":"P Kaaijk","year":"2013","journal-title":"Vaccine"},{"key":"ref37","unstructured":"RotsNY, KleijneDESafety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. 16th International Pathogenic Neisseria Conference, Rotterdam, 7-112 September 2008."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0264-410X(01)00371-1","article-title":"Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine","volume":"20","author":"E de Kleijn","year":"2001","journal-title":"Vaccine"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF00395832","article-title":"Strictly aseptic techniques for continuous centrifugation","volume":"46","author":"P Van Hemert","year":"1980","journal-title":"Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF01570067","article-title":"Clarification of animal cell cultures on a large scale by continuous centrifugation","volume":"14","author":"R Kempken","year":"1995","journal-title":"J Ind Microbiol"},{"key":"ref41","unstructured":"Gorringe A, Vincent P, Halliwell D, Reddin K (2006) Patent WO2006\/008504 A1: Stable compositions containing outer membrane vesicles, methods of manufacturing."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.vaccine.2003.08.027","article-title":"Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines","volume":"22","author":"C Arigita","year":"2004","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jama.1992.03480030070039","article-title":"Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine","volume":"267","author":"CP Howson","year":"1992","journal-title":"Jama"},{"key":"ref44","first-page":"2732","article-title":"Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005","volume":"151","author":"NA van der Maas","year":"2007","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2005.10.003","article-title":"Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine","volume":"24","author":"T Luijkx","year":"2006","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/IAI.01108-08","article-title":"Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response","volume":"77","author":"V Weynants","year":"2009","journal-title":"Infect Immun"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1574-695X.2010.00692.x","article-title":"Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model","volume":"60","author":"N Roy","year":"2010","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.vaccine.2011.06.001","article-title":"Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii","volume":"29","author":"MJ McConnell","year":"2011","journal-title":"Vaccine"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1016\/j.vaccine.2011.08.058","article-title":"A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection","volume":"29","author":"W Nieves","year":"2011","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/CVI.05217-11","article-title":"Outer membrane vesicles induce immune responses to virulence proteins and protect against colonization by enterotoxigenic Escherichia coli","volume":"18","author":"K Roy","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/pr1009756","article-title":"Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine","volume":"10","author":"T Pierson","year":"2011","journal-title":"J Proteome Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1016\/j.vaccine.2008.07.004","article-title":"Outer membrane vesicles as acellular vaccine against pertussis","volume":"26","author":"R Roberts","year":"2008","journal-title":"Vaccine"},{"key":"ref53","first-page":"7","article-title":"Gram-negative outer membrane vesicles in vaccine development","volume":"12","author":"BS Collins","year":"2011","journal-title":"Discov Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1074\/jbc.M307628200","article-title":"Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles","volume":"279","author":"NC Kesty","year":"2004","journal-title":"J Biol Chem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1073\/pnas.0805532107","article-title":"Delivery of foreign antigens by engineered outer membrane vesicle vaccines","volume":"107","author":"DJ Chen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Kim SH, Kim KS, Lee SR, Kim E, Kim MS, <etal>et al<\/etal>.. (2009) Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim Biophys Acta.","DOI":"10.1016\/j.bbamem.2009.08.001"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/jcm.9.2.186-188.1979","article-title":"Serotypes of <italic>Neisseria meningitidis<\/italic> isolated from patients in Norway during the first six months of 1978","volume":"9","author":"E Holten","year":"1979","journal-title":"J Clin Microbiol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/bit.22016","article-title":"Modeling <italic>Neisseria meningitidis<\/italic> B metabolism at different specific growth rates","volume":"101","author":"GJ Baart","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-5793(75)80272-9","article-title":"Electrophoretic resolution of the &quot;major outer membrane protein&quot; of Escherichia coli K12 into four bands","volume":"58","author":"B Lugtenberg","year":"1975","journal-title":"FEBS Lett"},{"key":"ref60","unstructured":"Gerhardt P, Murray RGE, Wood WA, Krieg NR (1994) Methods for general and molecular bacteriology. WashingtonDC:American Society for Microbiology."},{"key":"ref61","first-page":"767","article-title":"Gas chromatography of bacterial whole cell methanolysates; V. Fatty acid composition of Neisseriae and Moraxellae","volume":"82","author":"E Jantzen","year":"1974","journal-title":"Acta Pathol Microbiol Scand B Microbiol Immunol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1128\/CMR.4.4.422","article-title":"Applications of cellular fatty acid analysis","volume":"4","author":"DF Welch","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"ref63","first-page":"83","article-title":"Bacterial lipopolysaccharide extraction with phenol-water and further application of the procedure","volume":"5","author":"O Westphal","year":"1965","journal-title":"Methods Carbohydr Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1128\/IAI.00834-06","article-title":"Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis","volume":"74","author":"J Geurtsen","year":"2006","journal-title":"Infect Immun"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/ac9509519","article-title":"Analytical properties of the nanoelectrospray ion source","volume":"68","author":"M Wilm","year":"1996","journal-title":"Anal Chem"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ijc.2910410324","article-title":"Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes","volume":"41","author":"HW Ziegler-Heitbrock","year":"1988","journal-title":"Int J Cancer"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1128\/IAI.71.11.6367-6371.2003","article-title":"Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form","volume":"71","author":"TA Luijkx","year":"2003","journal-title":"Infect Immun"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0065157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T15:14:05Z","timestamp":1645629245000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0065157"}},"subtitle":[],"editor":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0065157","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.g004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0065157.s003","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}